Hochhaus A, Lin F, Reiter A, Skladny H, van Rhee F, Shepherd P C, Allan N C, Hehlmann R, Goldman J M, Cross N C
LRF Centre for Adult Leukaemia, Royal Postgraduate Medical School, Hammersmith Hospital, London, U.K.
Br J Haematol. 1995 Sep;91(1):126-31. doi: 10.1111/j.1365-2141.1995.tb05257.x.
A substantial minority of patients with chronic myeloid leukaemia (CML) achieve a complete response to treatment with interferon-alpha (IFN-alpha), defined as the disappearance of Philadelphia chromosome positive metaphases or, for patients who are Philadelphia chromosome negative but BCR-ABL positive, the disappearance of the leukaemic clone as assayed by Southern blot. We have measured the levels of BCR-ABL transcripts in 20 such patients by quantitative PCR. Results were standardized for both quality and quantity of cDNA by quantification of ABL as an internal control. All 20 patients had evidence of residual disease; the median number of transcripts was 750/micrograms RNA (range 10-22,000) and the median BCR-ABL/ABL ratio was 0.17% (range 0.0008-3.6%). Our findings show that CML has not been eradicated in any patient and that the quantity of residual disease in complete responders may vary by as much as four orders of magnitude.
相当一部分慢性髓性白血病（CML）患者对α干扰素（IFN-α）治疗有完全反应，其定义为费城染色体阳性中期相消失，或者对于费城染色体阴性但BCR-ABL阳性的患者，通过Southern印迹法检测白血病克隆消失。我们通过定量PCR测量了20例此类患者的BCR-ABL转录本水平。通过将ABL作为内对照进行定量，对cDNA的质量和数量进行了标准化。所有20例患者均有残留疾病的证据；转录本中位数为750/微克RNA（范围10-22,000），BCR-ABL/ABL中位数比率为0.17%（范围0.0008-3.6%）。我们的研究结果表明，没有任何患者的CML已被根除，完全缓解者的残留疾病量可能相差多达四个数量级。
